Coherus Oncology (CHRS) Total Current Liabilities (2013 - 2026)
Coherus Oncology recorded quarterly Total Current Liabilities of $132.3 million in Q1 2026, down 5.74% quarter-over-quarter from $140.4 million in Q4 2025, and down 48.11% year-over-year from $255.0 million in Q1 2025.
Coherus Oncology's Total Current Liabilities history runs 14 years deep, the most recent figure standing at $132.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 48.11% year-over-year to $132.3 million; the TTM figure through Mar 2026 stood at $132.3 million (down 48.11% YoY), while the FY2025 annual figure was $140.4 million, down 50.39% from the prior year.
- Total Current Liabilities came in at $132.3 million for Q1 2026 at Coherus Oncology, down from $140.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $538.3 million in Q1 2024 to a low of $123.4 million in Q1 2023.
- A 5-year average of $247.8 million and a median of $239.7 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities soared 336.2% in 2024 and slumped 52.62% in 2025, its largest moves.
- Coherus Oncology's Total Current Liabilities stood at $138.7 million in 2022, then surged by 139.21% to $331.8 million in 2023, then declined by 14.71% to $283.0 million in 2024, then tumbled by 50.39% to $140.4 million in 2025, then declined by 5.74% to $132.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $132.3 million, $140.4 million, and $372.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn | 132.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132.33 Mn |
| Dec 31, 2025 | 140.39 Mn |
| Sep 30, 2025 | 372.30 Mn |
| Jun 30, 2025 | 263.63 Mn |
| Mar 31, 2025 | 255.04 Mn |
| Dec 31, 2024 | 282.98 Mn |
| Sep 30, 2024 | 295.57 Mn |
| Jun 30, 2024 | 463.01 Mn |
| Mar 31, 2024 | 538.30 Mn |
| Dec 31, 2023 | 331.77 Mn |
| Sep 30, 2023 | 239.66 Mn |
| Jun 30, 2023 | 169.44 Mn |
| Mar 31, 2023 | 123.41 Mn |
| Dec 31, 2022 | 138.69 Mn |
| Sep 30, 2022 | 171.32 Mn |
| Jun 30, 2022 | 140.75 Mn |
| Mar 31, 2022 | 153.75 Mn |
| Dec 31, 2021 | 165.33 Mn |
| Sep 30, 2021 | 320.35 Mn |
| Jun 30, 2021 | 287.05 Mn |
| Mar 31, 2021 | 257.60 Mn |
| Dec 31, 2020 | 145.65 Mn |
| Sep 30, 2020 | 133.43 Mn |
| Jun 30, 2020 | 129.76 Mn |
| Mar 31, 2020 | 119.01 Mn |
| Dec 31, 2019 | 114.97 Mn |
| Sep 30, 2019 | 82.70 Mn |
| Jun 30, 2019 | 61.23 Mn |
| Mar 31, 2019 | 41.41 Mn |
| Dec 31, 2018 | 33.26 Mn |
| Sep 30, 2018 | 24.54 Mn |
| Jun 30, 2018 | 22.20 Mn |
| Mar 31, 2018 | 27.62 Mn |
| Dec 31, 2017 | 28.40 Mn |
| Sep 30, 2017 | 31.43 Mn |
| Jun 30, 2017 | 35.95 Mn |
| Mar 31, 2017 | 47.30 Mn |
| Dec 31, 2016 | 56.38 Mn |
| Sep 30, 2016 | 58.39 Mn |
| Jun 30, 2016 | 108.28 Mn |
| Mar 31, 2016 | 92.92 Mn |
| Dec 31, 2015 | 106.02 Mn |
| Sep 30, 2015 | 82.52 Mn |
| Jun 30, 2015 | 69.95 Mn |
| Mar 31, 2015 | 51.91 Mn |
| Dec 31, 2014 | 51.78 Mn |
| Sep 30, 2014 | 48.08 Mn |
| Dec 31, 2013 | 53.70 Mn |